What happened with BTMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Biote Corp. provides mainly U.S. clinics with training, software and ongoing support for hormone-replacement therapy using hormone pellets. Its Biote Method helps practitioners evaluate treatment options and manage their practices, but practitioners make the medical decisions. Clinics pay fees associated with pellet procedures recorded in Biote’s software. These fees cover the support package and pellet costs and supply most of the company’s revenue.
Biote also sells Biote-branded dietary supplements, mainly to partnered clinics that resell them to patients. Patients can also buy through practitioner-branded online stores. This smaller revenue stream depends heavily on practitioners recommending the products; the broader business depends on clinics and patients continuing to use the Biote Method. Products recommended through the method are typically not covered by insurance.
Biote-owned Asteria Health manufactures most of the hormone pellets used by its certified practitioners, with AnazaoHealth and Carie Boyd’s Prescription Shop supplying additional pellets. These compounded drugs are not FDA-approved, and their supply depends on facilities meeting federal and state requirements. U.S. law also prohibits anyone other than the compounding outsourcing facility from selling or transferring its compounded drugs.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Biote's results depend on recruiting and retaining hormone-therapy clinics and sustaining procedure volumes; watch direct competitors Evexias Health Solutions and SottoPelle, neither of which appears in this list.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate matters to Biote because economy-wide rates affect what it pays on its variable-rate borrowing, leaving more or less cash for clinic support and other operations.
Expected4.0%Last release4.0%
If it comes in above expectations
If the rate is above the estimate, higher rates can raise the cost of Biote’s variable-rate debt, leaving less cash for operating needs.
If it comes in below expectations
If the rate is below the estimate, lower rates can ease the cost of Biote’s variable-rate debt, leaving more cash for operating needs.
Biote Corp. earningsThis company
Biote Corp.'s report will show whether fees from its clinic platform are stabilizing and supplement sales are continuing to offset pressure on procedure revenue.
Read procedure revenue from the Biote Method alongside supplement revenue. If procedure revenue stabilizes or rises, pressure in the clinic business is easing; if it keeps falling even as supplements grow, product sales are not yet making up for weakness in the core clinic business.
